{"id":"706dfdb5fb65","type":"article","url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","title":"Canagliflozine bij diabetes type 2 met CKD: evaluatie van CV- en renale events","title_en":"Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["anemie-ckd","chronische-nierziekte","credence-trial","dapagliflozine","diabetes-type-2","diabetische-nefropathie","fidelio-dkd","figaro-dkd","flow-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.119.044359","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.119.044359","authors":["Christopher P Cannon","Vlado Perkovic","Rajiv Agarwal","James Baldassarre","George Bakris","David M Charytan","Dick de Zeeuw","Robert Edwards","Tom Greene","Hiddo J L Heerspink","Meg J Jardine","Adeera Levin","Jing-Wei Li","Bruce Neal","Carol Pollock","David C Wheeler","Hong Zhang","Bernard Zinman","Kenneth W Mahaffey"],"significance":7,"published":"2020-02-04","source_date":"2020-02-04","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This analysis evaluated canagliflozin's cardiovascular and renal effects in diabetic patients with CKD across both primary and secondary prevention settings, demonstrating consistent cardiorenal benefit across the risk spectrum.","created":"2026-07-03T10:28:25Z","updated":"2026-07-03T13:27:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse van canagliflozine op cardiovasculaire en renale events bij diabetespatiënten met CKD in primaire en secundaire preventie.","abstract_original":""}